Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes that one is bashing but seems to be for the purpose to harass retail investors and discourage people from posting and sharing.
ur ass mangled.
Why argue back and forth unless it is a form of entertainment for you. Just put the trolls on ignore. When they find out they are only talking to themselves they will get frustrated. I mean one person has over 2100 posts all bashing the stock within a bit over 4 months. It is obvious yes. They have free accounts and once they reach their max it is over for the day.
Good luck and have a great weekend. Enjoy life. Have fun. Don't hate.
where is the ASM fitting in? May 24th? 27th?? Then they have to be in Chicago ASCO.
Flopper and the others require the skeptics always include their unabridged sentiment at the bottom of each post.
Backpedaler.
Try harder flipper.
I said "if things go smoothly' then Aug-Sep is a reasonable time-frame for approval.
I expect nothing close to "going smoothly". Nor do I expect approval,
Yeah, unlike cvm, here at least we know the data is great. Once the mm's are silenced by news, it should fly. When is the big question. I almost bought ibrx yesterday after checking it out, now sorry I did not.
Thanks for the reply, and lets all make money.
You forget to mention the amended 10-K or 14A, whichever comes out, in the next week.
Can;t wait to see for certain what the long term investor appointed to the BOD actually holds. My guess is nothing.
By then it'll make more sense to everyone here to wait until the New Year.
Ex bets against himself.
Ex before: No approval in 2024.
Ex now: Approval reasonable Aug/Sept 2024.
That's correct, with a word like "Extensive" inserted, there's no need to PR delays.
"Extensive"
>>ORIGIN
late Middle English: from French extensif, -ive or late Latin extensivus, from extens-
'stretched out', from the verb extendere (see extend).
Well, the retail come in these OTC places
And the retail are all the same
You don't look at their faces
And you don't ask their names
You don't think of them as human
You don't think of them at all
You keep your mind on the money
Keeping your eyes on the fall
I'm your Danish dancer
A dancer for money
I'll do what they want me to do
I'm your Danish dancer
A dancer for money
Not any old stock will do...
Agree with you Robotdroid. This years have been very painful for us.
I continue confident on the science and that’s the reason why I’m holding shares. I think our day will come. Good luck to you and us all!!!
Congrats GC
Hopefully you can buy 150-200% of shares you sold from the profit you make here .
Flies in the face of some who were bashing you .
With the magic formula and so much money being made, why would you ever expect a finale? But they are getting quite old.
Thank very much Single Stock!!! Good look to you also in all your investments !!!
Thank you very much KRISGO!!! Yes, I think it’s related to their conference call Today and to fda approval they received this week. I wish you all the best too!!
To kick off the first business session of Asembia 2023, Ray Tancredi, divisional vice president at Walgreens, noted 6 major trends in the 2023 specialty therapy pipeline:https://t.co/McgUeOpUJk$nwbo #dcvax #glioblastoma @WalgreensNews @POTUS @FLOTUS @NIHDirector @NCIDirector pic.twitter.com/mpA1U2AuvP
— rj (@sharpie510) April 26, 2024
This is fantastic news! Convenience, cost savings, & reduction in hospital visits for patients.
— rj (@sharpie510) April 26, 2024
👏
The DCVax® Platform For All Solid Tumor Cancers$nwbo #dcvax #glioblastoma @WalgreensNews @POTUS @FLOTUS @NIHDirector @NCIDirectorhttps://t.co/5uzCqiFqWjhttps://t.co/6JnBRLZ3yF
I agree that August-September is a likely timeframe for a decision.
May is sorta interesting.
May 1: Defendant’s new MTD due.
May 6: “Several” month gap from February 6th begins. Time (minimum) from when NWBO assigned contractor to make GMP grade Eden.
May 10: 10q due.
May 24: Estimated 80 + (60 possible rfi) = 140th day since validation. Cemented?
May 31: Plaintiff’s response to MTD due.
Friendly bet George that it hasn't happened by August.
I would love to lose :)
There's about to be some beer in my empty glass though
I would just like to see some sort of finale here. Preferably a positive one. It's becoming exhausting.
Congratulations German! on your purchase of IBRX! I wish you all the best in your future endeavors.
Q: Why is it going up? due to their conference call today?
Thanks!
I wonder if anyone contacted the company about the status change with Revimmune?
Cognate , advent , revimmune … so it goes
Thank you very much Bas2020, appreciate it. I’m very happy. I think good times are coming here in NWBO also!!! :)
I wanna say friends with benefits, but it also may be to make Advent jealous?
Don't we look silly today :( lol
What is the relationship between NWBO and Revimmune?
Congrats on your IBRX investment... +29% today
The closer we get to approval the desperation increases. Laura is watching. If you believe she cannot find you, your a fool.
These shares at ATM and majority have been since they left the NASDAQ. That's why they went to the OTC. It's a lot easier with no interference from the NASDAQ
Your stock is gong to zero..
Peace out
All posts are my opinions
Says the professional fudster. What is your degree in? LAS? Can’t get a real job I take it.
This is the new winner of dumbest posts in the last century.
When we explain our NWBO investment to family it’s a bit like Jack explaining the magic beans he just bought to his mother when he got home.
We’re still in an earlier part of the story.
When we explain our NWBO investment to family it’s a bit like Jack explaining the magic beans he just bought to his mother when he got home.
In both cases, the explanation doesn’t go over well.
Thankfully Jack only had to wait one night.
Hopefully this is the year our beanstalk grows.
PSA
Your money is spiraling down in an endless Ponzi scheme. Talk to a professional please.
IMHO
Except that for NWBO that “sell” part never happens
Thanks a lot DocLogic for your words, for always being a gentleman and supporting NWBO. I am tightly keeping the shares I didn´t sell (an important amount I think), because I beleive in the science and if I have funds available, see improvement from management and price hasn't exploded, I'm planning to rebuy the shares I sold, even if I have to buy them at a higher, but still reachable price. That is my hope. Also, if I have analyses or thoufghts to share I for sure will do and will continue supporting NWBO.
Followers
|
1620
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
689593
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |